A long-term comparative study of calcitriol versus alphacalcidol in patients with secondary hyperparathyroidism on hemodialysis;Estudio comparativo a largo plazo entre calcitriol y alfacalcidol en pacientes con hiperparatiroidismo secundario en hemodiálisis

Nefrologia

Volumn 26, Issue 2, 2006, Pages 226-233

  Arenas Jiménez, Ma Dolores ^a   Muray, S ^a   Amoedo, M L ^a   Egea, J J ^a   Millan I ^a   Gil, M T ^a  

^a HOSPITAL PERPETUO SOCORRO   (Spain)

Author keywords

1 hydroxycholecalciferol; Calcitriol; Parathyroid hormone; Secondary hyperparathyroidism

Indexed keywords

1-HYDROXYCHOLECALCIFEROL; ALFACALCIDOL; CALCITRIOL; HYDROXYCOLECALCIFEROL;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; SECONDARY HYPERPARATHYROIDISM; TIME;

ADULT; AGED; AGED, 80 AND OVER; CALCITRIOL; FEMALE; HUMANS; HYDROXYCHOLECALCIFEROLS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 33748088523     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Rapoport J, Mostoslavski M, Ben-David A y cols.: Successful treatment of secondary hyperparathyroidism in hemodialysis patients with oral pulse 1-alpha-hydroxy-cholecalciferol therapy. Nephron 72: 150-4, 1996.
2. El-Reshaid K, El-Reshaid W, Sugathan T, Al-Mohannadi S, Sivanandan R: Comparison of the efficacy of two injectable forms of vitamin D3 and oral one-alpha in treatment of secondary hyperparathyroidism in patients on maintenance hemodialysis. Am J Nephrol 17: 505-10, 1997.
3. Brandi L, Egfjord M, Olgaard K: Pharmacokinetics of 1,25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uraemic men. Nephrol Dial Transplant 17: 829-42, 2002.
4. Ohno J, Kubota M, Hirasawa Y, Suzuky M, Mimura N, Minamikata T: Clinical evaluation of a 1 alpha-hydroxilcholecalciferol and 1-alpha25- dihydroxycolecalciferol in the treatment of renal osteodistrophy; in Norman AM. Schaefer K Von Herrath D, Grigoleit HG (eds): Vitamin D, chemical, biochemical and clinical endocrinology of calcium metabolism. Berlin de Gruyter 1982: 847-852
5. Kimura Y, Nakayama M, Kuriyama S, Watanabe S, Kawaguchi Y, Sakai O: Pharmacokinetics of active vitamins D3, 1 alpha-hydroxyvitamin D3 and 1 alpha, 25-dihydroxyvitamin D3 in patients on chronic hemodialysis. Clin Nephrol 35: 72-7, 1991.
6. Seino Y, Tanaka H, Yamaoka K, Yabuuchi H. Circulating 1 alpha,25-dihydroxyvitamin D levels after a single dose of 1 alpha,25- dihydroxyvitamin D3 or 1 alpha-hydroxyvitamin D3 in normal men. Bone Miner 2: 479-85, 1987.
7. Papapoulos SE, Vd Berg H, Frolich M, Valentijn RM: Circulating 1,25-dihydroxycholecalciferol after intravenous injections of 1 alpha-hydroxycholecalciferol in patients on regular haemodialysis. Nephrol Dial Transplant 3: 647-50, 1988.
8. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 74: 2136-43, 1984.
9. Fernández E, Borrás M, Pais B, Montoliu J: Low-calcium dialysate stimulates parathormone secretion and long-term use worsens secondary hyperparathyroidism. J Am Soc Nephrol 6: 132-5, 1995.
10. Brandi L, Daugaard H, Tvedegaard E y cols.: Long-term suppression of secondary hyperparathyroidism by intravenous 1 alpha-hydroxyvitamin D3 in patients on chronic hemodialysis. Am J Nephrol 12: 311-8, 1992.
11. Fournier A, Moriniere PH, Oprisiu R y cols.: 1-alpha-Hydroxy-vitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration. Nephron 71: 254-83, 1995.
12. Rodríguez M, Felsenfeld AJ, Williams C, Pederson JA, Llach F: The effect of long-term intravenous calcitriol administration on parathyroid function in hemodialysis patients. J Am Soc Nephrol 2: 1014-20, 1991.
13. Malberti F, Surian M, Cosci P: Effect of chronic intravenous calcitriol on parathyroid function and set point of calcium in dialysis patients with refractory secondary hyperparathyroidism. Nephrol Dial Transplant 7: 822-8, 1992.
14. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ: Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321: 274-9, 1989.
15. Cannella G, Bonucci E, Rolla D y cols.: Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol. Kidney Int 46: 1124-32, 1994.
16. Gallieni M, Brancaccio D, Padovese P y cols.: Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol. Kidney Int 42: 1191-8, 1992.
17. Sprague SM, Moe SM: Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol. Am J Kidney Dis 19: 532-9, 1992.
18. Llach F: Parathyroidectomy in chronic renal failure: indications, surgical approach and the use of calcitriol. Kidney Int 29: S62-8, 1990.
19. Meric F, Yap P, Bia MJ: Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy. Am J Kidney Dis 16: 459-64, 1990.
20. Morinière Ph, Maurouard C, Boudailliez B, Bouillon M, Mamphile R, Fournier A. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxivitamin D3 in association with Mg(OH)2 as sole phosphate binder. Nephron 60: 154-163, 1992.
21. Morinière Ph, El Esper N, Viron B y cols.: Improvement of severe hyperparathyroidism in dialysis patients by intravenous 1 alpha OH vitamin D3, oral calcium and low dialysate calcium. Kidney Int 43 (Supl. 41): 121-124, 1993.